10x Genomics 10-Q: Q3 Revenue $150.7M, Gross Margin Jumps to 75%, Cash $575.7M
TXG has more than doubled off its 52-week low of $12.8.
Summary
10x Genomics' Q3 10-Q shows revenue of $150.7M, a narrower $19.4M net loss and gross margin up to 75%, with $575.7M in cash and securities. New Xenium patent litigation and a $4.862M Scale Bio jury award headline the legal disclosures.
Key Events · Earnings and Guidance · TXG
-
Q3 Revenue $150.7M, Loss Narrows
Revenue rose to $150.7M from $149.0M a year ago, while net loss narrowed to $19.4M ($0.15 per share) from $27.5M ($0.22).
-
Gross Margin Jumps to 75%
Gross margin rose to 75% from 67%, driven by $5.9M lower inventory write-downs and $5.3M lower manufacturing costs.
-
Cash and Securities $575.7M
Cash, cash equivalents and marketable securities totaled $575.7M, up $52.3M since December 31, 2025; nine-month operating cash flow was $58.9M versus $95.3M a year ago.
-
New Xenium Patent Suit
Spatial Genomics and Caltech sued in August 2026 alleging the Xenium platform infringes five patents, seeking injunctive relief and unspecified damages; 10x counterclaimed in October 2026.
Analysis · TXG · Industrial Applications And Services
The 10-Q confirms the Q3 beat already flagged in the 2026-11-05 press release, but the detail is what matters: gross margin rose to 75% from 67% on lower inventory write-downs and manufacturing costs, and the balance sheet holds $575.7M in cash and securities. Against that, nine-month operating cash flow fell to $58.9M from $95.3M a year ago, and the legal docket expanded with a new Spatial Genomics/Caltech suit against Xenium and a Waters injunction request in Europe. The Scale Bio jury verdict against Parse ($4.862M awarded, willful infringement) is a potential upside but is under post-trial motions.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TXG was trading at $57.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $12.80 to $102.81. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.